Cell · 2021
A selective antibiotic for Lyme disease.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Leimer Nadja, Wu Xiaoqian, Imai Yu, Morrissette Madeleine, Pitt Norman, Favre-Godal Quentin, Iinishi Akira, Jain Samta, Caboni Mariaelena, Leus Inga V, Bonifay Vincent, Niles Samantha, Bargabos Rachel, Ghiglieri Meghan, Corsetti Rachel, Krumpoch Megan, Fox Gabriel, Son Sangkeun, Klepacki Dorota, Polikanov Yury S, Freliech Cecily A, McCarthy Julie E, Edmondson Diane G, Norris Steven J, D'Onofrio Anthony, Hu Linden T, Zgurskaya Helen I, Lewis Kim
Аннотация
Lyme disease is on the rise. Caused by a spirochete Borreliella burgdorferi, it affects an estimated 500,000 people in the United States alone. The antibiotics currently used to treat Lyme disease are broad spectrum, damage the microbiome, and select for resistance in non-target bacteria. We therefore sought to identify a compound acting selectively against B. burgdorferi. A screen of soil micro-organisms revealed a compound highly selective against spirochetes, including B. burgdorferi. Unexpectedly, this compound was determined to be hygromycin A, a known antimicrobial produced by Streptomyces hygroscopicus. Hygromycin A targets the ribosomes and is taken up by B. burgdorferi, explaining its selectivity. Hygromycin A cleared the B. burgdorferi infection in mice, including animals that ingested the compound in a bait, and was less disruptive to the fecal microbiome than clinically relevant antibiotics. This selective antibiotic holds the promise of providing a better therapeutic for Lyme disease and eradicating it in the environment.